Redsense Medical announced that the highly experienced global life science leader Pontus Nobréusis appointed new CEO. Nobréus combines a track record of driving sales through well-targeted commercialization with an unwavering commitment to innovation that truly benefits patients, and takes over the helm at Redsense to speed up its ongoing journey of growth. The qualified and internationally proven chief executive brings wide experience in diagnostics, medtech, and international business development and sales to the role.

He will succeed outgoing CEO Patrik Byhmer, co-founder and largest shareholder of the Company, who is leaving the position as CEO to transition into a new role as Chairman of the Board (pending the Annual General Meeting's decision). While the agreement is already signed, the exact date when the new CEO will assume responsibilities and enter into function is yet to be determined as Nobréus is currently settling his business with his current employer. Pontus Nobréus, born in 1964, has held leading business positions in diagnostics and medtech for more than 15 years, including employments in the United States and South Africa.

Nobréus joins Redsense from a position as CEO of Pro Health Pharma Sweden AB. He previously served as CEO of Glycorex Transplantation AB (publ) and prior to that as Business Development Director at Biovica International AB. He has also worked at HemoCue and Svar Life Science, and his experience extends across sales, channel management, business development, and marketing in international settings.